KalVista Pharmaceuticals (KALV) AI Stock Analysis

• Market Cap: $648.29M
• Dividend Yield: N/A
• Average Volume (3M): 540.16K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.00
• Revenue Growth: N/A
• EPS Growth: -18.75%
• Country: US
• Employees: 150
• Sector: Healthcare
• Sector Strength: 53
• Industry: Biotechnology
• EPS (TTM): -0.92
• Shares Outstanding: 49,715,637
• 10 Day Avg. Volume: 679,949
• 30 Day Avg. Volume: 540,160
• PEG Ratio: 1.70
• Price to Book (P/B): 3.59
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -9.26
• Enterprise Value/Market Cap: 0.31
• Enterprise Value/Revenue: 41.33
• Enterprise Value/Gross Profit: 261.32
• Enterprise Value/Ebitda: -0.32
• 1Y Price Target: $28.43
• Price Target Upside: 134.18% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

• Rating: 45 Neutral
• Price Target: ―

KalVista Pharmaceuticals exhibits substantial financial challenges with weak revenue generation and profitability. While technical indicators show mixed momentum, the company's strategic agreement with Kaken Pharmaceutical provides a potential growth avenue. However, the negative P/E ratio and lack of dividend yield negatively impact valuation. Overall, the stock's score reflects financial struggles counterbalanced by strategic opportunities.

Positive Factors

Market Readiness

KalVista Pharmaceuticals remains on track for a US launch of sebetralstat, with strong commercial readiness and engagement across prescribers, payors, and the patient community.

Product Potential

Sebetralstat is positioned as a potential first oral therapy for acute hereditary angioedema, offering a convenient alternative to current injectables.

Regulatory Process

The delay is seen as a suggestion of a positive approval outcome for sebetralstat given that FDA could have issued a CRL if there was a review issue instead of simply delaying their decision by 4 weeks.

Negative Factors

Market Competition

Investors often question the magnitude of the on-demand market, especially given the emergence of Orladeyo and less frequently dosed injectable options.

Regulatory Concerns

The FDA will not meet the previously PDUFA date for sebetralstat due to agency resource constraints and workload.

Regulatory Uncertainties

The FDA delay due to resource constraints is concerning for other ongoing reviews and upcoming PDUFA dates.

KalVista Pharmaceuticals Business Overview & Revenue Model

Company Description

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

KalVista Pharmaceuticals generates revenue through strategic partnerships, collaborations, and licensing agreements with larger pharmaceutical companies, which provide funding and resources to support its research and development activities. As a clinical-stage company, KalVista does not yet generate revenue from product sales but aims to do so upon successful development and commercialization of its product candidates. The company's financial performance is significantly influenced by milestone payments and royalties from successful partnerships, as well as potential future sales of approved therapies.

KalVista Pharmaceuticals Financial Statement Overview

Summary

KalVista Pharmaceuticals faces significant financial challenges with low revenue generation and profitability. The company has a modest gross profit margin but struggles with negative EBIT and net income. The balance sheet shows low leverage but is affected by continuous losses. Cash flow analysis indicates high cash burn and liquidity risks, highlighting the need for improved revenue streams and expense management.

Income Statement

KalVista Pharmaceuticals has faced significant challenges in generating revenue, with total revenue at $1.2 million in the TTM. Gross profit margin is modest at 63.26%, but the company is struggling with high negative EBIT and net income, leading to negative EBIT and net profit margins. The revenue growth is inconsistent, and the overall financial health from an income perspective is weak.

Balance Sheet

The balance sheet reveals a moderate debt-to-equity ratio of 0.04, indicating low leverage. However, the company has a negative return on equity due to continuous losses. The equity ratio stands at 52.58%, showing that over half of the assets are financed by equity, which is positive, but the company's financial stability is affected by ongoing losses.

Cash Flow

Cash flow analysis shows a negative operating cash flow of $127.6 million in the TTM, indicating cash outflows exceed inflows from operations, which is concerning. The company has a negative free cash flow and a weak cash flow to net income ratio, highlighting significant cash burn and potential liquidity risks.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
1.21M	0.00	0.00	0.00	12.69M	12.69M
	Gross Profit
763.00K	-86.17M	-802.00K	-743.00K	12.04M	12.65M
	EBIT
-181.42M	-140.44M	-110.87M	-96.61M	-57.92M	-40.53M
	EBITDA
-175.20M	-134.28M	-92.11M	-81.60M	-45.59M	-40.02M
	Net Income Common Stockholders
-175.87M	-126.64M	-74.85M	-68.51M	-44.49M	-29.12M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
253.20M	210.40M	149.38M	166.20M	248.93M	67.71M
	Total Assets
275.99M	235.40M	183.20M	203.88M	272.01M	92.53M
	Total Debt
5.78M	7.32M	8.23M	8.19M	5.91M	1.65M
	Net Debt
-161.51M	-24.47M	-48.01M	-22.54M	-44.68M	-14.14M
	Total Liabilities
130.87M	28.82M	22.18M	18.79M	14.82M	8.78M
	Stockholders Equity
145.13M	206.58M	161.03M	185.09M	257.19M	83.75M
Cash Flow		Free Cash Flow
-128.41M	-89.67M	-76.46M	-79.06M	-30.25M	-45.04M
	Operating Cash Flow
-127.65M	-89.23M	-75.26M	-78.13M	-30.17M	-44.82M
	Investing Cash Flow
-31.83M	-84.72M	41.41M	57.86M	-147.65M	16.75M
	Financing Cash Flow
305.17M	150.71M	58.12M	1.58M	212.12M	11.58M

KalVista Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 12.14
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KALV, the sentiment is Neutral. The current price of 12.14 is below the 20-day moving average (MA) of 12.75, below the 50-day MA of 12.39, and above the 200-day MA of 10.94, indicating a neutral trend. The MACD of 0.25 indicates Positive momentum. The RSI at 43.65 is Neutral, neither overbought nor oversold. The STOCH value of 16.10 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for KALV.

KalVista Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.34B	3.36	-45.10%	3.39%	16.81%	-0.03%
DNTH	47 Neutral	$585.95M	―	-28.73%	―	189.31%	51.03%
LENZ	46 Neutral	$811.17M	―	-24.47%	―	―	68.93%
KALV	45 Neutral	$648.29M	―	-150.50%	―	―	-18.75%
GHRS	45 Neutral	$789.00M	―	-16.20%	―	―	-9.46%
REPL	42 Neutral	$757.76M	―	-62.58%	―	―	4.28%
RCKT	40 Underperform	$310.29M	―	-60.45%	―	―	6.99%

KalVista Pharmaceuticals Corporate Events

KalVista Pharmaceuticals Signs Agreement with Kaken Pharmaceutical

On April 8, 2025, KalVista Pharmaceuticals entered into a License, Supply, and Distribution Agreement with Kaken Pharmaceutical for the commercialization of sebetralstat in Japan. This agreement includes an upfront payment of $11 million and potential milestone payments up to $24 million, plus royalties. Sebetralstat, if approved, would be the first oral on-demand treatment for HAE in Japan, marking a significant commercial opportunity for both companies.

Spark’s Take on KALV Stock

According to Spark, TipRanks’ AI Analyst, KALV is a Neutral.

KalVista Pharmaceuticals scores a 52.2, reflecting a blend of financial challenges and positive strategic moves. Significant weaknesses in financial performance and valuation are counterbalanced by strong technical momentum and promising corporate developments. Key risks include the company’s ongoing financial struggles, while the strategic appointment and technical indicators offer potential upside.

To see Spark’s full report on KALV stock, click here.